Efficacy of bortezomib in sarcomas with high levels of MAP17 (PDZK1IP1)

Oncotarget

Volumn 7, Issue 41, 2016, Pages 67033-67046

  Perez, Marco ^a   Peinado Serrano, Javier ^a   Garcia Heredia, Jose Manuel ^a,b   Felipe Abrio, Irene ^a   Tous, Cristina ^a   Ferrer, Irene ^a   Martin Broto, Javier ^a   Saez, Carmen ^a   Carnero, Amancio ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b UNIVERSITY OF SEVILLE   (Spain)

Author keywords

Biomarker; Bortezomib; MAP17; Pdx; Sarcomas

Indexed keywords

BORTEZOMIB; DOXORUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAP17 PROTEIN; MEMBRANE PROTEIN; TRABECTEDIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; PDZK1IP1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; AUTOPHAGY; CANCER PROGNOSIS; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GENE EXPRESSION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; ONCOGENE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SARCOMA; SURVIVAL ANALYSIS; SURVIVAL PREDICTION; ADOLESCENT; ANIMAL; AREA UNDER THE CURVE; BIOSYNTHESIS; DRUG SCREENING; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MOUSE; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BIOMARKERS, TUMOR; BORTEZOMIB; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MEMBRANE PROTEINS; MICE; MIDDLE AGED; PROGNOSIS; ROC CURVE; SARCOMA; SENSITIVITY AND SPECIFICITY; XENOGRAFT MODEL ANTITUMOR ASSAYS; YOUNG ADULT;

EID: 84993990742     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.11475     Document Type: Article

References (48)

1. Honoki K, Tsujiuchi T. Senescence bypass in mesenchymal stem cells: a potential pathogenesis and implications of prosenescence therapy in sarcomas. Expert Rev Anticancer Ther. 2013; 13:983-996.
2. Helman LJ, Meltzer P. Mechanisms of sarcoma development. Nat Rev Cancer. 2003; 3:685-694.
3. Mackall CL, Meltzer PS, HelmanLJ. Focus on sarcomas. Cancer Cell. 2002; 2:175-178.
4. Taylor BS, Barretina J, Maki RG, Antonescu CR, Singer S, Ladanyi M. Advances in sarcoma genomics and new therapeutic targets. Nat Rev Cancer. 2011; 11:541-557.
5. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA. 2010; 60:277-300.
6. Singer S, Demetri GD, Baldini EH, Fletcher CD. Management of soft-tissue sarcomas: an overview and update. Lancet Oncol. 2000; 1:75-85.
7. Svancarova L, BlayJY, Judson IR, van HoeselQG, van Oosterom AT, le Cesne A, Keizer HJ, Hermans C, van Glabbeke M, Verweij J, Hogendoorn PC, Nielsen OS. Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2002; 38:556-559.
8. Nielsen OS, Judson I, van Hoesel Q, le Cesne A, Keizer HJ, BlayJY, van Oosterom A, Radford JA, Svancarova L, Krzemienlecki K, Hermans C, van Glabbeke M, OosterhuisJW, Verweij J. Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2000; 36:61-67.
9. Izbicka E, Lawrence R, Raymond E, Eckhardt G, Faircloth G, Jimeno J, Clark G, Von Hoff DD. In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients. Ann Oncol. 1998; 9:981-987.
10. Le Cesne A, BlayJY, Judson I, Van Oosterom A, Verweij J, Radford J, Lorigan P, Rodenhuis S, Ray-Coquard I, Bonvalot S, Collin F, Jimeno J, Di Paola E, Van Glabbeke M, Nielsen OS. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J ClinOncol. 2005; 23:576-584.
11. Perez M, Munoz-Galvan S, Jimenez-Garcia MP, Marin JJ, Carnero A. Efficacy of CDK4 inhibition against sarcomas depends on their levels of CDK4 and p16ink4 mRNA. Oncotarget. 2015 Dec 1; 6:40557-40574. doi: 10.18632/oncotarget.5829.
12. Kocher O, Cheresh P, Brown LF, Lee SW. Identification of a novel gene, selectively up-regulated in human carcinomas, using the differential display technique. Clin Cancer Res. 1995; 1:1209-1215.
13. Kocher O, Cheresh P, Lee SW. Identification and partial characterization of a novel membrane-associated protein (MAP17) up-regulated in human carcinomas and modulating cell replication and tumor growth. Am J Pathol. 1996; 149:493-500.
14. Guijarro MV, Link W, Rosado A, Leal JF, Carnero A. MAP17 inhibits Myc-induced apoptosis through PI3K/AKT pathway activation. Carcinogenesis. 2007; 28:2443-2450.
15. Pribanic S, Gisler SM, Bacic D, Madjdpour C, Hernando N, Sorribas V, Gantenbein A, Biber J, Murer H. Interactions of MAP17 with the NaPi-IIa/PDZK1 protein complex in renal proximal tubular cells. Am J Physiol Renal Physiol. 2003; 285:F784-791.
16. Blasco T, AramayonaJJ, Alcalde AI, Catalan J, Sarasa M, Sorribas V. Rat kidney MAP17 induces cotransport of Na-mannose and Na-glucose in Xenopus laevis oocytes. Am J Physiol Renal Physiol. 2003; 285:F799-810.
17. Carnero A. MAP17 and the double-edged sword of ROS. BiochimBiophys Acta. 2012; 1826:44-52.
18. Jaeger C, Schaefer BM, Wallich R, Kramer MD. The membrane-associated protein pKe#192/MAP17 in human keratinocytes. J Invest Dermatol. 2000; 115:375-380.
19. Lanaspa MA, Giral H, BreusegemSY, Halaihel N, Baile G, Catalan J, Carrodeguas JA, Barry NP, Levi M, Sorribas V. Interaction of MAP17 with NHERF3/4 induces translocation of the renal Na/Pi IIa transporter to the trans-Golgi. Am J Physiol Renal Physiol. 2007; 292:F230-242.
20. Guijarro MV, Leal JF, Blanco-Aparicio C, Alonso S, Fominaya J, Lleonart M, Castellvi J, Ramony Cajal S, Carnero A. MAP17 enhances the malignant behavior of tumor cells through ROS increase. Carcinogenesis. 2007; 28:2096-2104.
21. Guijarro MV, Vergel M, Marin JJ, Munoz-Galvan S, Ferrer I, Ramony Cajal S, Roncador G, Blanco-Aparicio C, Carnero A. p38alpha limits the contribution of MAP17 to cancer progression in breast tumors. Oncogene. 2012; 31:4447-4459.
22. Guijarro MV, Vergel M, Marin JJ, Munoz-Galvan S, Ferrer I, Cajal SR, Roncador G, Blanco-Aparicio C, Carnero A. p38alpha limits the contribution of MAP17 to cancer progression in breast tumors. Oncogene. 2012; 31:4447-4459.
23. Guijarro MV, Leal JF, Fominaya J, Blanco-Aparicio C, Alonso S, Lleonart M, Castellvi J, Ruiz L, Ramon YCS, Carnero A. MAP17 overexpression is a common characteristic of carcinomas. Carcinogenesis. 2007c; 28:1646-1652.
24. Perez M, Praena-Fernandez JM, Felipe-Abrio B, Lopez-Garcia MA, Lucena-Cacace A, Garcia A, Lleonart M, Roncador G, Marin JJ, Carnero A. MAP17 and SGLT1 protein expression levels as prognostic markers for cervical tumor patient survival. PLoS ONE. 2013; 8:e56169.
25. Guijarro MV, Leal JF, Fominaya J, Blanco-Aparicio C, Alonso S, Lleonart M, Castellvi J, Ruiz L, Ramon YCS, Carnero A. MAP17 overexpression is a common characteristic of carcinomas. Carcinogenesis. 2007; 28:1646-1652.
26. Carnero A. MAP17, a ROS-dependent oncogene. Front Oncol. 2012; 2:112.
27. de Miguel-Luken MJ, Chaves-Conde M, de Miguel-Luken V, Munoz-Galvan S, Lopez-Guerra JL, Mateos JC, Pachon J, Chinchon D, Suarez V, Carnero A. MAP17 (PDZKIP1) as a novel prognostic biomarker for laryngeal cancer. Oncotarget. 2015; 6:12625-12636. doi: 10.18632/oncotarget.3470.
28. de Miguel-Luken MJ, Chaves-Conde M, Carnero A. A genetic view of laryngeal cancer heterogeneity. Cell Cycle. 2016; 15:1202-1212.
29. Munoz-Galvan S, Gutierrez G, Perez M, Carnero A. MAP17 (PDZKIP1) Expression Determines Sensitivity to the Proteasomal Inhibitor Bortezomib by Preventing Cytoprotective Autophagy and NFkappaB Activation in Breast Cancer. Mol Cancer Ther. 2015; 14:1454-1465.
30. Javier Martin-Broto, Pousa AL, PeñasRDl, MuroXGd, Gutierrez A, Martinez-Trufero J, Cruz J, Alvarez R, Cubedo R, Redondo A, Maurel J, Carrasco JA, López-Martin JA, Sala á, Meana A, Ramos R et al. Randomized Phase II Study Of Trabectedin And Doxorubicin Compared With Doxorubicin Alone As First Line Treatment In Patients With Advanced Soft Tissue Sarcomas: A Spanish Group For Research On Sarcoma (GEIS) Study. J ClinOncol.2016; 653329.
31. Moneo V, Serelde BG, Fominaya J, Leal JF, Blanco-Aparicio C, Romero L, Sanchez-Beato M, CigudosaJC, TerceroJC, Piris MA, Jimeno J, Carnero A. Extreme sensitivity to Yondelis (Trabectedin, ET-743) in low passaged sarcoma cell lines correlates with mutated p53. J Cell Biochem. 2007; 100:339-348.
32. Moneo V, Serelde BG, Leal JF, Blanco-Aparicio C, Diaz-Uriarte R, Aracil M, TerceroJC, Jimeno J, Carnero A. Levels of p27(kip1) determine Aplidin sensitivity. Mol Cancer Ther. 2007; 6:1310-1316.
33. Kane RC, Dagher R, Farrell A, Ko CW, Sridhara R, Justice R, Pazdur R. Bortezomib for the treatment of mantle cell lymphoma. Clin Cancer Res. 2007; 13:5291-5294.
34. Mujtaba T, Dou QP. Advances in the understanding of mechanisms and therapeutic use of bortezomib. Discov Med. 2011; 12:471-480.
35. Liu J, Shaik S, Dai X, Wu Q, Zhou X, Wang Z, Wei W. Targeting the ubiquitin pathway for cancer treatment. BiochimBiophys Acta. 2015; 1855:50-60.
36. Fribley A, Zeng Q, Wang CY. Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Mol Cell Biol. 2004; 24:9695-9704.
37. Obeng EA, Carlson LM, GutmanDM, Harrington WJ, Jr., Lee KP, Boise LH. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood. 2006; 107:4907-4916.
38. Weniger MA, Rizzatti EG, Perez-Galan P, Liu D, Wang Q, Munson PJ, Raghavachari N, White T, Tweito MM, Dunleavy K, Ye Y, Wilson WH, Wiestner A. Treatmentinduced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphoma. Clin Cancer Res. 2011; 17:5101-5112.
39. Ri M, Iida S, Nakashima T, Miyazaki H, Mori F, Ito A, Inagaki A, Kusumoto S, Ishida T, Komatsu H, Shiotsu Y, Ueda R. Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress. Leukemia. 2010; 24:1506-1512.
40. Deming DA, Ninan J, Bailey HH, Kolesar JM, Eickhoff J, Reid JM, Ames MM, McGovern RM, Alberti D, Marnocha R, Espinoza-Delgado I, Wright J, Wilding G, SchelmanWR. A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors. Invest New Drugs. 2014; 32:323-329.
41. Poklepovic A, Youssefian LE, Winning M, Birdsell CA, Crosby NA, Ramakrishnan V, Ernstoff MS, Roberts JD. Phase I trial of bortezomib and dacarbazine in melanoma and soft tissue sarcoma. Invest New Drugs. 2013; 31:937-942.
42. de Miguel-Luken MJ, Chaves-Conde M, Carnero A. A Genetic view of Laryngeal Cancer heterogeneity. Cell Cycle. 2016; In press.
43. Carnero A, Beach DH. Absence of p21WAF1 cooperates with c-myc in bypassing Ras-induced senescence and enhances oncogenic cooperation. Oncogene. 2004; 23:6006-6011.
44. Castro ME, Ferrer I, Cascon A, Guijarro MV, Lleonart M, Cajal SR, Leal JF, Robledo M, Carnero A. PPP1CA contributes to the senescence program induced by oncogenic Ras. Carcinogenesis. 2008; 29:491-499.
45. Quereda V, Martinalbo J, Dubus P, Carnero A, Malumbres M. Genetic cooperation between p21Cip1 and INK4 inhibitors in cellular senescence and tumor suppression. Oncogene. 2007; 26:7665-7674.
46. Leal JF, Ferrer I, Blanco-Aparicio C, Hernandez-Losa J, Ramon YCS, Carnero A, Lleonart ME. S-adenosylhomocysteine hydrolase downregulation contributes to tumorigenesis. Carcinogenesis. 2008; 29:2089-2095.
47. Savola S, Klami A, Tripathi A, Niini T, Serra M, Picci P, Kaski S, Zambelli D, Scotlandi K, Knuutila S. Combined use of expression and CGH arrays pinpoints novel candidate genes in Ewing sarcoma family of tumors. BMC Cancer. 2009; 9:17.
48. Kuijjer ML, Hogendoorn PC, Cleton-Jansen AM. Genomewide analyses on high-grade osteosarcoma: making sense of a genomically most unstable tumor. Int J Cancer. 2013; 133:2512-2521.